Alliance for Regenerative Medicine Announces Appointment of Timothy D. Hunt as Chief Executive Officer
The Alliance for Regenerative Medicine announces the appointment of a
Timothy D. Hunt as general manager
WASHINGTON, DC – August 10, 2022
The Alliance for Regenerative Medicine (ARM), the leading international advocacy organization representing the cell and gene therapy industry, today officially announced that its Board of Directors has appointed Timothy D. Hunt as Chief Executive Officer organisation. Hunt will succeed Janet Lynch Lambert, who announcement in April, his intention to step down as CEO and who served on the board search committee. The hunt will begin at ARM on September 6.
“We are delighted to welcome Tim to the ARM team at such a critical time for our industry,” said Emile Nuwaysir, Chairman of ARM’s Board and Research Committee, and President and CEO. the management of Ensoma, a live genomic drug company. “Tim’s two decades of experience advocating for biotech companies, his knowledge of key issues facing the field of cell and gene therapy, and his expertise in leading teams make him the ideal choice. to guide ARM in building the future of medicine. Tim has a deep philosophy of engagement with key stakeholders who will support ARM members and help integrate cell and gene therapies into mainstream medical practice.
Hunt was most recently Director of Culture and Corporate Affairs at Xilio Therapeutics, a biotechnology company developing tumor-selective immuno-oncology therapies for cancer patients. Previously, he was Director of Corporate Affairs at Editas Medicine, a pioneer in CRISPR gene editing, where he led global corporate policy and government affairs, bioethics, communications, market development and environmental initiatives. matters of human resources. He has also held senior public affairs positions at Cubist Pharmaceuticals and Biogen.
Hunt was a member of the advisory group for the Duke-Margolis Center for Health Policy’s Value-Based Payments for Medical Products Consortium. He was also a board member of the non-profit organization Life Science Cares and chaired the ethics committee of the American Society of Gene and Cell Therapy (ASGCT). Hunt previously served as a member of ARM’s Gene Editing Task Force and the Biotechnology Innovation Organization’s Gene Editing Task Force. He received a BA in history and philosophy from Boston College and a JD from the Columbus School of Law at the Catholic University of America.
“I am honored to succeed Janet as CEO of the Alliance for Regenerative Medicine and for the incredible opportunity to build on her legacy of ARM development to make her the industry’s leading advocate and resource for industry,” Hunt said. “Cell and gene therapies are already transforming the lives of patients, and we are on the cusp of even more breakthroughs in rare and prevalent diseases. Our mission is both urgent and clear: to engage all of our key stakeholders to ensure that the patients we serve have access to the sustainable and potentially curative therapies of the present and the future.
“Tim is an excellent choice to continue to grow and strengthen this amazing organization and help realize the potential of regenerative medicine,” said Lambert, whose tenure includes doubling ARM’s global membership to 425 members. , strengthening the organization’s advocacy in the United States and Europe, and building the ARM team.
Cell and gene therapies to treat blood cancers, spinal muscular atrophy and an inherited form of blindness are approved in the United States and Europe. 2022 could be a peak year for new gene therapy approvals for rare diseases, and regulators in the United States and Europe could approve the first such therapies for hemophilia and sickle cell disease in late 2022 and 2023. More than 2,400 regenerative medicine clinical trials – 60% of which targeted prevalent diseases, including diabetes and cardiovascular disease, were active globally by the end of 2021. ARM is committed to working with stakeholders to ensure that patients benefit from this rapidly evolving pipeline of transformative therapies.
About the Alliance for Regenerative Medicine
The Alliance for Regenerative Medicine (ARM) is the leading international advocacy organization dedicated to realizing the promise of Advanced Therapy Medicines (ATMPs). ARM promotes legislative, regulatory, reimbursement and manufacturing initiatives in Europe and internationally to advance this innovative and transformative sector, which includes cell therapies, gene therapies and tissue-engineered therapies. The first products to market have demonstrated profound, long-lasting and potentially curative benefits that are already helping thousands of patients worldwide, many of whom have no other viable treatment options. Hundreds of additional product candidates contribute to a strong pipeline of potentially game-changing ATMPs. Over its 12-year history, ARM has become the global voice of the industry, representing the interests of over 425 members worldwide and over 80 members in 15 European countries, including small and large companies, academic research institutes, major medical centers and patient groups. . To learn more about ARM or to become a member, visit http://www.alliancerm.org.
Media ask for information
For more information or media inquiries, please contact Stephen Majors, Senior Director of Public Affairs for ARM, at [email protected].